June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Intra-arterial chemotherapy rescue for recurrent or persistent subretinal seeds in retinoblastoma: Tumor control and globe salvage in 30 eyes
Author Affiliations & Notes
  • Prashanth G. Iyer
    Sydney Kimmel Medical College, Philadelphia, PA
  • Emil A Say
    Ocular Oncology Service, Wills Eye Hospital, Philadelphia, PA
  • Murat Hasanreisoglu
    Ocular Oncology Service, Wills Eye Hospital, Philadelphia, PA
  • Sara Lally
    Ocular Oncology Service, Wills Eye Hospital, Philadelphia, PA
  • Pascal Jabbour
    Thomas Jefferson University Hospital, Philadelphia, PA
  • Carol L Shields
    Ocular Oncology Service, Wills Eye Hospital, Philadelphia, PA
  • Footnotes
    Commercial Relationships Prashanth Iyer, None; Emil Say, None; Murat Hasanreisoglu, None; Sara Lally, None; Pascal Jabbour, None; Carol Shields, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1664. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Prashanth G. Iyer, Emil A Say, Murat Hasanreisoglu, Sara Lally, Pascal Jabbour, Carol L Shields; Intra-arterial chemotherapy rescue for recurrent or persistent subretinal seeds in retinoblastoma: Tumor control and globe salvage in 30 eyes. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1664.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To describe the efficacy of intra-arterial chemotherapy (IAC) for control of persistent or recurrent subretinal seeds in retinoblastoma.

Methods: In this retrospective non-comparative interventional case series, there were thirty eyes in 29 patients with retinoblastoma who have failed previous treatment with systemic chemotherapy, plaque radiation, or focal therapy and persistent or recurrent subretinal seeds. Superselective ophthalmic artery chemotherapy infusion under fluoroscopic guidance with melphalan (3, 5, or 7.5 mg) and additional topotecan (1 mg) and/or carboplatin (30 mg) was administered as necessary. The main outcome measures were tumor control and globe salvage.

Results: The mean patient age was 19 months. Secondary IAC was given to patients with recurrent or persistent subretinal seeds who failed previous treatment regimens (n=30 eyes). Each eye received a mean of 3 IAC per eye (median, 2; range, 1-7). After IAC with a mean follow-up of 14 months, 27 of the 30 eyes (90%) had subretinal seed regression after completion of IAC cycles. Long-term control with global salvage was maintained in 19 eyes (63%), with enucleation being required for recurrent subretinal seeds in 3 eyes (27%) and for recurrent subretinal and vitreous seeds in 3 eyes (27%).

Conclusions: IAC is effective as a secondary agent in the management of subretinal seeds in retinoblastoma achieving complete regression of subretinal seeds in 90% of eyes.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×